Generic Hetlioz LQ Availability
See also: Generic Hetlioz
Hetlioz LQ is a brand name of tasimelteon, approved by the FDA in the following formulation(s):
HETLIOZ LQ (tasimelteon - suspension;oral)
-
Manufacturer: VANDA PHARMS INC
Approval date: December 1, 2020
Strength(s): 4MG/ML [RLD]
Has a generic version of Hetlioz LQ been approved?
No. There is currently no therapeutically equivalent version of Hetlioz LQ available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hetlioz LQ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Highly purifid pharmaceutical grade tasimelteon
Patent 10,071,977
Issued: September 11, 2018
Assignee(s): VANDA PHARMACEUTICALS INC.A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Patent expiration dates:
- February 12, 2035✓✓
- February 12, 2035
-
Treatment of circadian rhythm disorders
Patent 10,149,829
Issued: December 11, 2018
Assignee(s): Vanda Pharmaceuticals Inc.Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Patent expiration dates:
- January 25, 2033✓
- January 25, 2033
-
Method of treatment
Patent 10,179,119
Issued: January 15, 2019
Assignee(s): VANDA PHARMACEUTICALS INC.Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
Patent expiration dates:
- August 29, 2035✓
- August 29, 2035
-
Patent 10,376,487
Patent expiration dates:
- July 27, 2035✓
- July 27, 2035
-
Patent 10,610,510
Patent expiration dates:
- January 25, 2033✓
- January 25, 2033
-
Patent 10,610,511
Patent expiration dates:
- October 10, 2034✓
- October 10, 2034
-
Patent 10,829,465
Patent expiration dates:
- February 12, 2035✓✓
- February 12, 2035
-
Benzofuran and dihydrobenzofuran melatonergic agents
Patent 5,856,529
Issued: January 5, 1999
Inventor(s): Catt; John D. & Johnson; Graham & Keavy; Daniel J. & Mattson; Ronald J. & Parker; Michael F. & Takaki; Katherine S. & Yevich; Joseph P.
Assignee(s): Bristol-Myers Squibb CompanyNovel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.
Patent expiration dates:
- December 9, 2022✓✓✓
- December 9, 2022
-
Treatment of circadian rhythm disorders
Patent 9,539,234
Issued: January 10, 2017
Assignee(s): Vanda Pharmaceuticals, Inc.Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Patent expiration dates:
- January 25, 2033✓
- January 25, 2033
-
Treatment of circadian rhythm disorders
Patent 9,730,910
Issued: August 15, 2017
Assignee(s): Vanda Pharmaceuticals, Inc.Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Patent expiration dates:
- May 17, 2034✓
- May 17, 2034
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 1, 2023 - NEW PRODUCT
More about Hetlioz LQ (tasimelteon)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Drug class: miscellaneous anxiolytics, sedatives and hypnotics
Consumer resources
- Other brands
- Hetlioz
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.